Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Ecallantide for treatment of acute attacks of hereditary angioedema.

Martello JL, Woytowish MR, Chambers H.

Am J Health Syst Pharm. 2012 Apr 15;69(8):651-7. doi: 10.2146/ajhp110227. Review.

PMID:
22472866
2.

Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability.

Bernstein JA, Qazi M.

Expert Rev Clin Immunol. 2010 Jan;6(1):29-39. Review.

PMID:
20383888
3.

Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.

Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T.

J Allergy Clin Immunol. 2007 Aug;120(2):416-22. Epub 2007 Jun 7.

PMID:
17559913
4.

Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.

MacGinnitie AJ, Campion M, Stolz LE, Pullman WE.

Allergy Asthma Proc. 2012 Mar-Apr;33(2):178-85. doi: 10.2500/aap.2012.33.3528.

PMID:
22525395
5.

Use of ecallantide in pediatric hereditary angioedema.

MacGinnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R.

Pediatrics. 2013 Aug;132(2):e490-7. doi: 10.1542/peds.2013-0646. Epub 2013 Jul 22.

6.

Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema.

Bernstein JA, Shea EP, Koester J, Iarrobino R, Pullman WE.

Allergy. 2012 Sep;67(9):1173-80. doi: 10.1111/j.1398-9995.2012.02864.x. Epub 2012 Jul 5.

7.

Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema.

Stolz LE, Sheffer AL.

Expert Rev Clin Immunol. 2012 Jan;8(1):25-32. doi: 10.1586/eci.11.81.

PMID:
22149337
8.

EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.

Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, Pullman WE.

Ann Allergy Asthma Immunol. 2010 Jun;104(6):523-9. doi: 10.1016/j.anai.2010.04.012.

PMID:
20568386
9.

Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema.

Stolz LE, Horn PT.

Drugs Today (Barc). 2010 Aug;46(8):547-55. doi: 10.1358/dot.2010.46.8.1507205. Review.

PMID:
20830315
10.

Response time for ecallantide treatment of acute hereditary angioedema attacks.

Riedl M, Campion M, Horn PT, Pullman WE.

Ann Allergy Asthma Immunol. 2010 Dec;105(6):430-436.e2. doi: 10.1016/j.anai.2010.09.005. Epub 2010 Oct 25.

PMID:
21130380
11.

Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.

Lumry WR, Bernstein JA, Li HH, MacGinnitie AJ, Riedl M, Soteres DF, Craig TJ, Campion M, Iarrobino R, Stolz LE, Pullman WE.

Allergy Asthma Proc. 2013 Mar-Apr;34(2):155-61. doi: 10.2500/aap.2013.34.3653. Erratum in: Allergy Asthma Proc. 2013 May-Jun;34(3):291.

PMID:
23484891
12.

Therapeutic approaches in hereditary angioedema.

Antoniu SA.

Clin Rev Allergy Immunol. 2011 Aug;41(1):114-22. doi: 10.1007/s12016-011-8254-2. Review.

PMID:
21279474
13.

New treatment options for acute edema attacks caused by hereditary angioedema.

Thomas MC, Shah S.

Am J Health Syst Pharm. 2011 Nov 15;68(22):2129-38. doi: 10.2146/ajhp100718. Review.

PMID:
22058099
14.

Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials.

Banta E, Horn P, Craig TJ.

Allergy Asthma Proc. 2011 Jul-Aug;32(4):319-24. doi: 10.2500/aap.2011.32.3440.

PMID:
21781409
15.

Analysis of hereditary angioedema attacks requiring a second dose of ecallantide.

Li HH, Campion M, Craig TJ, Soteres DF, Riedl M, Lumry WR, MacGinnitie AJ, Shea EP, Bernstein JA.

Ann Allergy Asthma Immunol. 2013 Mar;110(3):168-72. doi: 10.1016/j.anai.2012.12.004. Epub 2013 Jan 8.

PMID:
23548526
16.

Ecallantide: in acute hereditary angioedema.

Garnock-Jones KP.

Drugs. 2010 Jul 30;70(11):1423-31. doi: 10.2165/11205850-000000000-00000. Review.

PMID:
20614949
17.

Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.

Sheffer AL, MacGinnitie AJ, Campion M, Stolz LE, Pullman WE.

Ann Allergy Asthma Immunol. 2013 Mar;110(3):184-188.e2. doi: 10.1016/j.anai.2012.12.007. Epub 2013 Jan 5.

PMID:
23548529
18.

The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema.

Levy JH, O'Donnell PS.

Expert Opin Investig Drugs. 2006 Sep;15(9):1077-90. Review.

PMID:
16916274
19.

Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks.

Craig TJ, Li HH, Riedl M, Bernstein JA, Lumry WR, MacGinnitie AJ, Stolz LE, Biedenkapp J, Chyung Y.

J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):206-212.e4. doi: 10.1016/j.jaip.2014.09.001. Epub 2014 Oct 29.

20.

Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.

Riedl M.

Clin Ther. 2012 Mar;34(3):623-30. doi: 10.1016/j.clinthera.2012.02.003. Epub 2012 Mar 2.

PMID:
22386830

Supplemental Content

Support Center